Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody

Anifrolumab (anifrolumab) is an antagonist human monoclonal antibody that targets interferon α receptor 1 (IFNAR1). Anifrolumab has been developed to treat autoimmune diseases and is currently in clinical trials. To decipher the molecular basis of its mechanism of action, we engaged in multiple epit...

Full description

Saved in:
Bibliographic Details
Published in:MAbs
Main Authors: Peng, Li, Oganesyan, Vaheh, Wu, Herren, Dall’Acqua, William F, Damschroder, Melissa M
Format: Artigo
Language:Inglês
Published: Taylor & Francis 2015
Subjects:
Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622752/
https://ncbi.nlm.nih.gov/pubmed/25606664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1007810
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items